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Efficacy and safety of a 12-week therapy with a new formulation  
of fluticasone propionate at doses of 125 and 250 μg 
administered through a new generation cyclohaler twice daily,  
in comparison to fluticasone propionate 500 μg dry powder 
inhaler twice daily in patients with moderate asthma
Skuteczność i bezpieczeństwo terapii nowej formulacji flutykazonu w dawkach 125  
i 250 μg z inhalatora cyclohaler nowej generacji w porównaniu z lekiem referencyjnym 
w dawce 500 μg z inhalatora suchego proszku u chorych na przewlekłą umiarkowaną astmę
The study was financed by Laboratoires SMB S.A.
Abstract
Introduction: Inhaled fluticasone is used in the treatment of chronic bronchial asthma. Its high efficacy and good safety profile have 
been proven by clinical trials and observations. Its unique pharmacokinetic properties make it distinguishable from other drugs from 
this group. In vitro tests run on an artificial model of the airways and pharmacokinetic studies conducted on healthy volunteers have 
shown that the new formulation of this drug is outstanding due a twofold better lung deposition, compared to the reference medicine. 
The aim of this study was to evaluate the efficacy and safety of the new formulation of fluticasone propionate administered through 
new generation cyclohaler (CNG), compared to original fluticasone administered through dry powder inhaler (DPI) in patients with 
chronic moderate asthma. 
Material end methods: The study included 457 patients. 376 subjects were randomized to one out of the three groups: 
127 subjects — to the group treated with the new formulation of fluticasone at a dose of 125 μg BID, 125 subjects — to the group 
treated with new formulation of fluticasone at a dose of 250 μg BID, and 124 subjects — to the group treated with the reference drug — 
fluticasone DPI 500 μg BID. At the beginning of the study, the groups did not differ in demographical or clinical aspects. Active therapy 
lasted 12 weeks. The primary endpoint was a mean change in morning PEF during a 12-week course of therapy (∆mPEF of 15 L/min 
was considered as statistically significant). Additionally, other functional parameters of the respiratory system — clinical symptoms 
and the use of rescue drugs were studied. During the whole study the safety of patients was monitored by recording adverse events; in 
addition, a systemic exposure to fluticasone was evaluated by testing the changes of cortisol in serum and in a 24-hour collection of urine 
in a subgroup consisting of 45 patients. Statistical analysis was conducted on both groups: intention-to-treat (ITT) and per protocol (PP). 
Results: In PP as well as in ITT analysis, a mean change in morning PEF at the end of the therapy from the beginning of the active 
treatment was statistically significant in all therapeutic groups. The efficacy of the treatment with fluticasone at doses of 125 μg 
BID and 250 μg and the reference medicines did not differ statistically significantly after a 12-week course of therapy or during the 
whole period of treatment. During the study, significant improvement in the range of other functional parameters such as evening 
PEF, FEV1, clinical symptoms and the use of rescue drugs was observed in all therapeutic groups, without significant differences 
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in efficacy between the study groups. The comparison of efficacy of fluticasone at a dose of 125 μg BID with the generic product 
at a dose of 250 μg BID showed a weak dose-response relationship concerning the change in morning PEF, which arises from 
the almost flat dose-response curve in the range of medium and high doses for this drug. No significant quantitative or qualitative 
differences were shown between the groups in the recorded adverse events, qualified as related to treatment with fluticasone. 
There were no significant changes revealed in cortisol concentration in serum or in a 24-hour collection of urine between the initial 
level and the final visit in any of the groups. 
Conclusions: Fluticasone administered through the new generation cyclohaler, compared to original fluticasone DPI, allows a twofold 
reduction in drug dose, retaining in new formulation clinical efficacy that corresponds to the reference drug at twice the dose. New formu-
lation of fluticasone administered through the new generation cyclohaler has a safety profile clinically comparable to the reference drug.
Key words: bronchial asthma, fluticasone, new generation cyclohaler, non-inferiority study
Pneumonol. Alergol. Pol. 2013; 81: 527–536
Streszczenie
Wstęp: Flutykazon w postaci wziewnej stosowany jest w leczeniu przewlekłej astmy oskrzelowej. Ma udowodnioną w badaniach 
klinicznych i obserwacyjnych wysoką skuteczność i dobry profil bezpieczeństwa. Wyróżnia się spośród innych leków należących 
do tej grupy unikatowymi właściwościami farmakokinetycznymi. Badania in vitro na sztucznym modelu dróg oddechowych jak 
i badania farmakokinetyczne przeprowadzane na zdrowych ochotnikach wykazały, że w nowej formulacji lek ten cechuje się 
dwukrotnie lepszą depozycją płucną w porównaniu z preparatem referencyjnym. 
Celem tego badania była ocena skuteczności i bezpieczeństwa nowej formulacji propionianu flutykazonu podawanego z inhala-
tora nowej generacji typu cyklohaler (CNG) w porównaniu z oryginalnym produktem flutykazonu w inhalatorze proszkowym DPI 
u chorych na przewlekłą umiarkowaną astmę. 
Materiał i metody: Do badania włączono 457 pacjentów, 376 osób zrandomizowano przydzielając losowo do jednej z  trzech 
badanych grup:  127 osób do grupy leczonej flutykazonem w nowej formulacji w dawce 125 μg BID, 125 osób do grupy leczonej 
flutykazonem w nowej formulacji 250 μg BID i 124 osoby do grupy z lekiem referencyjnym — flutykazon DPI 500 μg BID. Badane 
grupy nie różniły się na początku badania pod względem demograficznym ani klinicznym. Aktywna terapia trwała 12 tygodni.  Pierw-
szorzędowym punktem końcowym była średnia zmiana porannego PEF podczas 12-tygodniowego okresu leczenia (za znamienną 
statystycznie różnicę uznano ∆mPEF o 15 l/min). Badano ponadto inne parametry czynnościowe układu oddechowego, objawy 
kliniczne i zużycie leków ratunkowych. W czasie trwania całego badania monitorowano bezpieczeństwo pacjentów rejestrując zda-
rzenia niepożądane, dodatkowo oceniano ekspozycję systemową na flutykazon, badając w 45-osobowej podgrupie zmiany kortyzolu 
w surowicy i dobowej zbiórce moczu. Analizę statystyczną przeprowadzono zarówno na grupie intention-to-treat jak i per protocol. 
Wyniki: Zarówno w analizie PP, jak i ITT średnia zmiana porannego PEF na koniec okresu leczenia od początku aktywnej terapii była 
istotna statystycznie we wszystkich grupach terapeutycznych. Efektywność terapii flutykazonem zarówno w  dawce 125 μg BID, 
jak i 250 μg BID oraz preparatem referencyjnym nie różniła się istotnie statystycznie po 12 tygodni terapii, jak również w całym okresie 
leczenia. Również w zakresie innych parametrów czynnościowych jak wieczorny PEF, FEV1, objawy kliniczne i zużycie leków ratunkowych 
obserwowano istotną poprawę we wszystkich grupach terapeutycznych w czasie trwania badania, bez istotnej różnicy w efektywności 
pomiędzy badanymi grupami. Porównując efektywność dawki flutykazonu 125 μg BID z 250 μg BID produktu odtwórczego wykazano 
słabą zależność dawka–odpowiedź w zakresie zmiany parametru porannego PEF, co wynika z niemal płaskiej krzywej dawka–odpowiedź 
w zakresie dawek średnich i wysokich dla tego leku. Nie wykazano też istotnych różnic ilościowych i jakościowych między grupami 
w rejestrowanych zdarzeniach niepożądanych zakwalifikowanych jako związane z leczeniem flutykazonem. W żadnej z grup nie odno-
towano istotnych zmian w stężeniu kortyzolu  w surowicy i dobowej zbiórce moczu między poziomem wyjściowym i wizytą końcową. 
Wnioski: Flutykazon CNG w porównaniu z oryginalnym produktem flutykazonu DPI, pozwala na dwukrotne obniżenie dawki tego leku 
przy zachowaniu efektywności klinicznej odpowiadającej lekowi referencyjnemu w dwukrotnie wyższej dawce. Flutykazon w nowej 
formulacji podawany z inhalatora typu  CNG ma porównywalny klinicznie  profil bezpieczeństwa do leku referencyjnego.
Słowa kluczowe: astma oskrzelowa, flutykazon, inhalator nowej generacji typu cyklohaler, badanie równoważności
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Introduction
Bronchial asthma is currently one of the 
most frequent chronic diseases of the respiratory 
system. There are nearly 4 million people with 
asthma in Poland [1]. The background of asthma is 
chronic inflammation of the airways, which causes 
bronchial hyperreactivity and clinical symptoms. 
Therefore, the basis for therapy are inhaled gly-
cocorticosteroids, which are considered to be the 
strongest anti-inflammatory drugs, and which are 
recommended for all types of chronic asthma, 
irrespective of aetiology, severity and control [2]. 
Fluticasone distinguishes itself from other 
inhaled glycocorticosteroids by its high affinity 
to intracellular glycocorticosteroid receptor (18 
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times higher than dexamethasone), and its high 
lipophilic nature, which results in strong and 
long-lasting activity of the drug in the bronchi. 
Simultaneously, fluticasone demonstrates a very 
poor bioavailability from the oral cavity and ali-
mentary tract (< 1%), it binds rapidly and in large 
proportion with plasma protein, and it comes un-
der first-pass effect in the liver, which significantly 
reduces the risk of systemic side-effects [3].
The aim of the present study was to evaluate 
the efficacy and safety of a new formulation of 
fluticasone propionate at a dose of 125 and 250 μg 
administered twice a day (BID) for 12 weeks, 
compared to the original fluticasone DPI 500 μg 
in patients with moderate asthma.
Material and methods
It was a Phase III trial and was designed as 
a multicentre (23 centres: 16 in Poland and 7 in 
Ukraine), randomized, open-label, parallel-group 
and positive control study. The centres received con-
sent to the study from local Bioethics Commissions. 
The scheme of the study is presented in Figure 1.
The study groups
The following criteria for participation in the 
study were applied.
Inclusion criteria
1. Patients of both sexes, from 18 to 70 years of age.
2. Moderate bronchial asthma diagnosed at least 
3 months prior to the first visit.
3. Reversibility of airway obstruction (increase in 
FEV1 of at least 12% after administration of 400 μg 
of salbutamol) shown during the first visit.
4. Predicted FEV1 value in the range 50 to 85% 
on screening and randomization visits.
5. Ability to follow the procedures of the study, 
including the use of inhalators, peak expira-
tory flow meter and spirometry.
6. Non-use of short-acting β2-agonist at least 6 
hours before visits at the centre.
7. Informed consent to participation in the 
study.
8. The use of an efficient contraceptive method 
by women of reproductive age and negative 
serum pregnancy test on the first visit, and 
negative urine pregnancy test on the rand-
omization visit.
 Exclusion criteria
1. Severe, life-threatening bronchial asthma or 
hospitalization due to exacerbation of asthma 
for 3 months prior to the first visit.
2. Uncontrolled or untreated clinically signifi-
cant immunological, hormonal, haematolo-
gical, psychiatric or neurological disorders, 
hepatopathy, nephropathy, diseases of the 
alimentary system or neoplasms.
3. The presence or history of cardiac dysrhyth-
mia and diagnosed diseases of cardiovascular 
system, including coronary heart disease, 
circulatory failure and uncontrolled arterial 
hypertension (diastolic pressure ≥ 95 mm Hg).
4. Infection of the respiratory system requiring 
antibiotic therapy 8 weeks before the first visit.
5. Significant diseases of the respiratory system 
other than asthma.
6. Smoking more than 10 cigarettes/per day or 
more than 10 pack-years in their history.
7. Seasonal asthma or history of seasonal exa-
cerbations of asthma.
8. The use of prohibited drugs.
9. Participation in another clinical trial 3 mon-
ths prior to the first visit.
Figure 1. The scheme of the study
Rycina 1. Schemat badania
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10. Other diseases or factors that, in the opinion 
of the researcher, may disrupt participation 
in the study.
11. Hypersensitivity or allergy to the drugs used 
in the study.
12. Diabetes.
13. Irregular PEF measurements and taking of 
the studied drugs (more than 20% of measu-
rements omitted or doses of the studied drug 
not taken).
14. The use of systemic steroids 8 weeks prior to 
the first visit.
The scheme of the study
The active period of the study lasted 12 weeks 
and was preceded by a 2-week screening period, 
during which patients were given placebo (sin-
gle-blind study). On the first day of the active 
period participants were randomly assigned 
to one of the three therapeutic arms. In the 
first arm patients were administered fluticasone 
125 μg BID through new generation cyclohaler, 
in the second one — fluticasone 250 μg BID also 
through new generation cyclohaler, in the third 
one — fluticasone DPI 500 μg BID. Only doses 
administered through new generation cyclohaler 
were double-blinded. Each patient had 6 planned 
visits during the study. 
The drugs used in the study 
During the initial period, patients inhaled 
capsules with placebo through a metered-dose, 
new generation cyclohaler, Fantasmino®. 
During the active period the studied drug, 
fluticasone, was administered through a new ge-
neration cyclohaler, Fantasmino®, at doses of 125 
μg (Flutixon® 125 μg) or 250 μg (Flutixon® 250 μg).
The reference drug was fluticasone 500 μg 
(Flixotide Disc® 500).
The rescue medication was Ventolin® 100 μg 
(GlaxoSmithKline).
Administration of the investigational drug
Each drug was administered twice a day (in 
the morning and in the evening). The number of 
used capsules of the studied fluticasone and the 
doses of original fluticasone DPI was registered in 
the documentation during each visit. A criterion 
for continuation in the study was administration 
of ≥ 80% of the doses of the drug.
Efficacy evaluation
The aim of the study was to evaluate the clinical 
efficacy of a new formulation of fluticasone at doses 
of 125 and 250 μg BID in comparison to the reference 
drug, fluticasone DPI 500 μg BID. We intended to 
demonstrate that the new formulation of the drug at 
the studied doses is as effective as the reference drug.
The primary endpoint was a mean change in 
morning PEF during 12 weeks of therapy (from 
the initial value — T0, to the value in the 12th 
week — T12). The initial value was the mean 
of 14 days of the screening period. A mean PEF 
was calculated during the 6th visit, from all data 
collected between the 5th and 6th visit.
Secondary endpoints were:
A. mean change in evening PEF (T0:T12),
B. mean change in FEV1 (T0:T12),
C. mean change in overall severity of asthma 
symptoms (T0:T12). The following asth-
ma symptoms were assessed: wheezing, co-
ugh and dyspnoea on a scale from 0 — lack 
of symptoms up to 3 — serious symptoms, 
D. sleep disturbances due to asthma (T0:T12),
E. use of the rescue medication (T0:T12). 
Safety evaluation
The secondary aim of the study was to eva-
luate the safety of new formulation of fluticasone 
at doses used in the study and to compare it with 
the safety profile of the reference drug.
The safety of the drugs was evaluated thro-
ugh the analysis of the occurrence and nature 
of adverse events, the frequency and reasons for 
withdrawal from the study, vital parameters, de-
viations from physical examination and laboratory 
investigation results. In the subgroup consisting 
of 45 subjects (15 subjects from each therapeutic 
arm) morning cortisol concentration in serum and 
in a 24-hour urine collection was determined. 
Statistical analysis
Values of p < 0.05 were assumed as statisti-
cally significant. Clinical efficacy measured in 
a primary variable was compared between the 
groups by using the ANOVA model. The lower 
limit of a bilateral 95% confidence interval for 
the difference of a mean change in morning PEF 
between the studied therapies above -15 L/min in 
both intention-to-treat and per protocol analyses 
was considered as a criterion for non-inferior 
efficacy of the two doses of fluticasone. 
Secondary endpoints — change in evening 
PEF was analysed similarly to morning PEF, 
whereas the remaining parameters were analysed 
by using ANOVA: changes of a given parameter 
between initial data and endpoint were compared.
The frequency of patients’ withdrawal from 
the study in different groups was compared with 
the use of Kaplan-Meier analysis.
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The analysis of adverse events was carried 
out using of descriptive statistics and tests for 
qualitative data analysis.
Additional analysis was made in the subgro-
up, where the cortisol levels in serum and urine 
were assessed. The change was assessed with the 
ANOVA method.
The size of the study group
It was calculated that the availability of com-
plete data from 100 patients per each therapeutic 
group, with standard deviation from morning 
PEF 50 L/min, will allow to find a statistically 
significant difference by 15 L/min of morning PEF 
change, with 80% force and 5% level of signifi-
cance for paired comparisons.
Results
Characteristics of the study groups
A  total of 457 patients were included in 
the study. Of these, 356 patients made the stu-
dy group in accordance with the protocol (per 
protocol group, PP). Intention-to-treat analysis 
(ITT group) included 376 patients who were all 
randomized and treated with at least one dose 
of the studied drug. A description of patients in 
the separate therapeutic groups is presented in 
Table 1. Randomization of patients is presented 
in Figure 2. In all patients the use of the studied 
drug and the number of PEF measurements were 
more than 80%. 
Efficacy evaluation
Primary endpoint — a mean change in morning 
PEF after 12 weeks of therapy
In PP and ITT analyses, a mean change in 
morning PEF at the end of the treatment period, 
compared to the initial period, was statistically 
significant in all therapeutic groups. No signifi-
cant differences concerning the mean change in 
morning PEF between the groups were observed 
during the 12th week of the therapy, or during the 
Table 1. Characteristic of therapeutic groups
Tabela 1. Charakterystyka grup terapeutycznych
Fluticasone CNG 
125
Fluticasone CNG
250
Fluticasone DPI 500 P
Number of patients 127 125 124 -
Women/men 82/45 78/47 70/54 -
Age (years) mean ± SD 42.26 ± 12.9 42.57 ± 13.33 42.57 ± 13.80 0.2751
Height [cm] mean ± SD 167.53 ± 8.49 168.9 ± 10.18 168.9 ± 13.12 0.4923
Weight [kg] mean ± SD 74.18 ± 14.03 74.86 ± 14.69 74.86 ± 15.79 0.8544
Tobacco smokers 22 21 20 0.9683
Heart rate/min 71.99 ± 7.94 72 ± 7.5 72 ± 7.43 0.5694
Systolic pressure [mm Hg] 126 ± 44 122.58 ± 9.48 124.49 ± 10.08 0.3022
Diastolic pressure [mm Hg] 79.12 77.32 ± 7.09 78.15 0.531
Respiratory rate/min 16.76 17.07 ± 2.23 16.92 0.4917
FEV1 [L] mean ± SD 2.2 ± 0.59 2.25 ± 0.63 2.26 ± 0.62 0.3342
FEV1% PREDICTED mean ± SD 71.31 ± 9.35 70.16 ± 9.42 71.16 ± 8.37 0.491
ΔFEV1% (reversibility test) 24.75 ± 13.13 25.3 ± 12.59 25.97 ± 12.97 -
FVC [L] mean ± SD 3.25 ± 0.88 3.37 ± 0.94 3.37 ± 0.92 0.4659
mPEF [L/min] mean ± SD 357 ± 94.03 360.56 ± 80.92 369.68 ± 109.96 0.5771
ePEF [L/min] mean ± SD 371.10 ± 93.13 378.62 ± 80.33 385.02 ± 108.56 0.5078
Wheezing mean points ± SD 1.18 ± 0.7 1.12 ± 0.73 1.07 ± 0.68 0.4704
Cough mean points ± SD 1.1 ± 0.68 1.0 ± 0.73 0.98 ± 0.65 0.3376
Dyspnea mean points ± SD 1.38 ± 0.65 1.37 ± 0.69 1.25 ± 0.69 0.2392
Sleep disorders mean points ± SD 1.84 ± 0.66 1.81 ± 0.66 1.76 ± 0.63 0.6068
Rescue medication mean N/d ± SD 3.88 ± 3.22 3.67 ± 3.44 3.83 ± 3.53 0.7546
All abbreviations in the text
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Figure 2. Randomization of patients in the study
Rycina 2. Losy pacjentów w badaniu
Table 2. The results of a mean change in morning PEF and standard deviations after 12 weeks of active treatment
Tabela 2. Wyniki średniej zmiany porannego PEF i odchyleń standardowych po 12 tygodniach aktywnego leczenia
Fluticasone CNG 125 Fluticasone CNG 250 Fluticasone DPI 500 P*
Analysis PP ITT PP ITT PP ITT PP ITT
Number of patients 123 127 120 125 113 124
ΔmPEF L/min 25.9 ± 42.6 25.9 ± 42.6 31.9 ± 46.6 34 ± 47.9 24.3 ± 52.0 25.2 ± 51.8 0.4058 0.2571
P** 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
PP  — per protocol; ITT — intention-to-treat; PEF — peak respiratory flow
P* analysis between the groups 
P** analysis in the groups
whole period of treatment. A similar efficacy of 
fluticasone 125 and 250 μg BID, compared to the 
reference drug, was demonstrated after 12 weeks 
of the therapy as well as during the whole period 
of treatment (Table 2).
However, in both PP and ITT analyses, a ten-
dency towards improvement in mPEF was ob-
served in the group treated with fluticasone 
250 μg BID, compared to patients treated with 
fluticasone 125 μg BID (Table 3).
Secondary endpoints
In PP analysis, in all therapeutic groups, 
a  significant improvement was observed in all 
secondary endpoints after 12 weeks of the thera-
py, compared to the initial period (Table 4). No 
significant differences were found between the 
groups in the mean change of secondary endpo-
ints after 12 weeks of the therapy. Similar results 
were obtained in ITT analysis (Table 4). 
Compliance — evaluation of the use of 
the studied drugs and PEF measurements 
during the study
During the whole study, patients from all 
study groups were administered more than 98% 
of the planned doses of the studied drugs. Only 
one randomized patient omitted more than 20% 
of the drug doses between the 3rd and 4th visit; 
in the remaining period of treatment he met the 
criteria of the drug administration by more than 
80%. The mean number of PEF measurements 
also exceeded 98% of the planned measurements 
for all therapeutic groups. None of the patients 
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omitted 20% of the planned measurements, and 
so nobody was excluded from the study for this 
reason.
Safety evaluation
Safety analysis was carried out on the ITT 
group. 
Adverse events
Generally, 143 adverse events were noted (61 
— in the group treated with fluticasone 125 μg, 
30 — in the group treated with fluticasone 250 μg, 
and 52 — in the group treated with fluticasone 
DPI 500 μg) in 81 patients (29 patients from the 
group treated with fluticasone 125 μg, 23 — from 
the group treated with fluticasone 250 μg, and 29 — 
from the group treated with fluticasone DPI μg 500). 
The frequency of adverse events was significantly 
lower in the group treated with fluticasone 250 μg 
than in the remaining groups (p = 0.0005).
Of these, 48 cases of adverse events were 
expected and 95 were unexpected. 62.2% of all 
events were qualified as mild symptoms, 26.6% 
— as moderate, and 4.9% — as severe. In all study 
groups, treatment-related events with frequency 
exceeding 1% included: hoarseness, dry cough 
and sore throat. The frequency of treatment-rela-
ted events did not exceed 5% in any gropus, the-
refore, a comparative analysis was not carried out.
During the active treatment three serious 
adverse events occurred (uterine bleeding, in-
fective exacerbations of asthma and pregnancy), 
but they were recognized as not related to the 
studied drug.
Table 3. Non-inferiority analysis for ΔmPEF
Tabela 3. Analiza typu non-inferiority dla ΔmPEF
95% confidence interval
ΔmPEF analysis PP ITT
limit of the interval Lower Upper Lower Upper
ΔmPEF fluticasone 125 vs. fluticasone 250 –18.26 4.66 –20.18 2.78
ΔmPEF fluticasone 125 vs. fluticasone DPI 500 –11.37 11.78 –12.22 10.96
ΔmPEF fluticasone 250 vs. fluticasone DPI 500 –4.72 18.74 –3.61 19.75
PP  — per protocol; ITT — intention-to-treat; PEF — peak respiratory flow
Table 4. The results for secondary variables after 12 weeks of the therapy compared to the initial data in PP and ITT analysis
Tabela 4. Wyniki dla zmiennych drugorzędowych po 12 tygodniach terapii w porównaniu z danymi wyjściowymi w analizie PP i ITT
Fluticasone CNG 125 Fluticasone CNG 250 Fluticasone DPI 500 P*
Analysis PP ITT PP ITT PP ITT PP ITT
Number of patients 123 127 120 125 113 124
Δ ePEF (L/min)
mean ± SD, P**
21.2 ± 42.4
0.0001
21.2 ± 42.4
0.0001
24.6 ± 42.1
0.0001
25.9 ± 42.8
0.0001
19.7 ± 46.9
0.0001
20.6 ± 47.1
0.0001
0.6802 0.5401
Δ FEV1 (L)
mean ± SD, P**
0.28 ± 0.40
0.0001
0.29 ± 0.40
0.0001
0.32 ± 0.43
0.0001
0.31 ± 0.43
0.0001
0.30 ± 0.42
0.0001
0.31 ± 0.42
0.0001
0.8801 0.8212
Δ FEV1 %N
mean ± SD, P**
9.43 ± 13.38
0.0001
9.79 ± 13.4
0.0001
10.30 ± 14.5
0.0001
10.20 ± 14.4
0.0001
9.65 ± 13.12
0.0001
10.1 ± 13.03
0.0001
0.8564 0.9384
Δ FVC (L)
mean ± SD, P**
0.27 ± 0.50
0.0001
0.28 ± 0.49
0.0001
0.25 ± 0.56
0.0001
0.25 ± 0.55
0.0001
0.33 ± 0.49
0.0001
0.33 ± 0.48
0.0001
0.5259 0.4145
Δ pkt of symptoms 
mean ± SD, P**
–0.29 ± 0.48
0.0001
–0.29 ± 0.48
0.0001
–0.34 ± 0.57
0.0001
–0.34 ± 0.56
0.0001
–0.29 ± 0.55
0.0001
–0.31 ± 0.56
0.0001
0.4807 0.4971
Δ pkt of sleep  
disorders
mean ± SD, P**
–0.32 ± 0.55
0.0001
–0.32 ± 0.55
0.0001
–0.30 ± 0.63
0.0001
–0.31 ± 0.62
0.0001
–0.24 ± 0.59
0.0001
–0.25 ± 0.59
0.0001
0.7673 0.7937
Δ use of SABA
mean ± SD, P**
–1.73 ± 2.61
< 0.0001
–1.73 ± 2.61
< 0.0001
1.36 ± 2.81
< 0.0001
1.37 ± 2.8
<0.0001
–1.62 ± 2.72
< 0.0001
–1.7 ± 2.81
< 0.0001
0.7026 0.6046 
PP — per protocol; ITT — intention-to-treat; PEF — peak respiratory flow; other abbreviations in the text 
P* analysis between the groups 
P** analysis in the groups
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Laboratory results, vital functions and physical 
examination
No differences were observed in quantity or 
quality of deviation from the norm in laboratory 
investigations between the study groups. No signifi-
cant differences were discovered in measurements 
of vital functions or physical examination between 
the three therapeutic groups during the study.
Cortisol concentrations
No significant differences were observed 
in initial serum cortisol concentration in the 
morning, in cortisol concentration in a 24-hour 
collection of urine before the active therapy, or 
after 12-week treatment, between the three gro-
ups. Significant changes in cortisol concentration 
in serum or in a 24-hour collection of urine be-
tween the initial level and the final visit were not 
observed in any of the groups (Table 5). 
The frequency of exclusions from treatment  
with the studied drug
In total, 20 subjects were withdrawn from the 
study after randomization: 4 subjects from the 
group treated with fluticasone 125 μg, 5 from the 
group treated with fluticasone 250 μg, and 11 from 
the group treated with fluticasone DPI 500 μg. 
Therapeutic groups were comperatable in respect 
of number (p = 0.0716) and reasons for exclusion 
of patients from the study. 
Discussion
The studied drug — fluticasone propionate 
— administered through a new generation inhaler 
is a generic, new formulation drug. In compa-
rison with the original drug, it is characterized 
by a  twofold improved lung deposition, equal 
molecular weight and a  smaller drug fraction 
remaining in the oral cavity after inhalation. This 
was proved by in vitro tests, run on an artificial 
model of the airways [4] and pharmacokinetic 
studies, conducted on healthy volunteers with 
single (paper in press) and multiple doses (paper 
in press).
Their results allowed the hypothesis to be 
proposed that a therapeutic effect equivalent to 
that of the original drug may be obtained by using 
half the dose of the new formulation of fluticaso-
ne. In order to confirm this hypothesis, a 12-week 
clinical trial was planned. It was carried out on 
patients with chronic moderate asthma in accor-
dance with guidelines by the EMA (European 
Medicines Agency) [5] concerning requirements 
for bioequivalence studies of a generic and refe-
rence drug.
According to the characteristics of the refe-
rence drug, in moderate asthma it is recommen-
ded to use fluticasone DPI at doses from 250 μg 
twice a day (BID) to 500 μg BID. In the present 
clinical study equivalents of the lowest therapeu-
tic dose used in moderate asthma — fluticasone 
125 μg DPI BID (equivalent to fluticasone DPI 
250 μg BID), and of the highest dose — fluticasone 
250 μg (equivalent to fluticasone DPI 500 BID), 
were assumed. The lowest dose was assumed in 
order to show efficacy of the lowest dose used, 
whereas the highest dose was to prove the safety 
of the drug according to guidelines by the EMA [5]. 
In bioequivalence studies of inhaled anti-in-
flammatory drugs, in order to show comparable 
efficacy of both products, the EMA recommends 
Table 5. Cortisol level in serum and urine, and its changes during 12 weeks of therapy 
Tabela 5. Stężenie kortyzolu w surowicy i moczu i jego zmiany w okresie 12 tygodni terapii
Fluticasone CNG 125 Fluticasone CNG 250 Fluticasone DPI 500 P*
Number of patients 11 10 11
Cortisol in serum (N 116-1060 nmoL/L)
During the randomized visit 301.7 ± 117.7 304.8 ± 96.8 412.82 ± 354.86 0.4381
Δ during the final visit –26.2 ± 126.4 –59.9 ± 95.9 –153 ± 398.4 0.6635
P** 0.8311 0.098 0.2324
Cortisol in urine (N 88-671 nmoL/24h)
During the randomized visit 281.27 ± 149.35 323.4 ± 196.05 232.91 ± 146.7 0.4604
Δ during the final visit –44.5 ± 145.9 –81.2 ± 275.5 –33.2 ± 169.6 0.9879
P** 0.3352 0.4023 0.5513
P* analysis between the groups 
P** analysis in the groups
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that the study lasts at least 6–8 weeks, to exclude 
the loss of asthma control [5]. To evaluate the 
safety of a generic product, it is recommended 
that the study lasts 12 weeks. The present study 
lasted 12 weeks; therefore, both conditions — ef-
ficacy and safety evaluation of the drug — were 
fulfilled. In order to confirm the systemic safety 
of the studied drug, a subgroup of patients was 
distinguished, in whom, additionally, the influ-
ence of the therapy on cortisol concentration in 
blood and in a 24-hour collection of urine, was 
evaluated, and thus the additional recommenda-
tions of the EMA were fulfilled [5].
The study results showed a significant im-
provement in morning PEF for the two evaluated 
doses of the studied drug. A beneficial change was 
also observed in secondary parameters of thera-
peutic efficacy: evening PEF, FEV1 and FEV1%, 
FVC, severity severity of asthma symptoms and 
the use of rescue medications. It proves the 
clinical efficacy of the two studied doses of the 
generic product.
The comparison of the efficacy of fluticasone 
at a dose of 125 μg BID with the generic product 
at a dose of 250 μg BID showed a weak dose- 
-response relationship in the range of change in 
morning PEF.
The majority of benefits resulting from the 
use of inhaled glycocorticosteroids are achieved 
by the use of low doses (up to 250 μg/d expressed 
in fluticasone, which equals 90% of the efficacy 
obtained with a dose of 1000 μg/d). Holt et al. 
estimated that the maximal therapeutic effect 
measured in the change of functional pulmonary 
parameters is achieved by the use of fluticasone 
DPI 500 μg/d [6]. Due to the fact that for these 
drugs the dose-response curve in the range of me-
dium and higher doses has an almost flat course, 
a further increase in the dose results in a small 
clinical effect in respect of asthma control and 
functional pulmonary parameters, yet it increases 
the risk of intolerance and adverse, particularly 
local, events. The use of higher doses in clinical 
practice is justified by patients who are resistant 
to low doses of inhaled glycocorticosteroids, but 
who respond to high doses. 
The comparison of the results concerning the 
efficacy of treatment with the generic product to 
treatment with the reference drug, demonstrated 
that the efficacy of the new formulation of flu-
ticasone 250 μg BID administered through new 
generation cyclohaler is equal to the efficacy of 
fluticasone DPI 500 μg BID in the range of primary 
and secondary variables. It confirms the previo-
us observations made during in vitro tests and 
pharmacokinetic studies, that two times better 
pulmonary deposition and equal molecular weight 
for a new formulation of the drug administered 
through new generation cyclohaler, compared to 
fluticasone DPI, allow the dose of the drug to be 
halved, retaining the clinical efficacy correspon-
ding to the reference drug at a twofold higher dose.
The present study has not shown a higher 
efficacy of fluticasone DPI 500 μg BID, compared 
to the efficacy of fluticasone 125 μg BID admini-
stered through new generation cyclohaler. This 
confimes the previously-described flat dose-re-
sponse curve for fluticasone at doses higher than 
250 μg/d for fluticasone DPI. The study by Wolf et 
al. [7] did not show a dose-response relationship 
for fluticasone in metered-dose inhaler (MDI) 100, 
200 and 500 μg administered BID.
Therefore, the results of the present study 
confirm the efficacy of treatment with the new 
formulation of fluticasone at doses of 125 μg and 
250 μg BID in patients with moderate asthma. 
The higher studied dose is recommended only 
for patients who cannot control the disease with 
a dose of 125 μg BID, which is equal to fluticasone 
DPI 250 μg BID.
During the study the tolerance and safety of 
the studied drug, in comparison to the reference 
drug, were also evaluated. A safety profile compa-
rable to the original drug was proven for the two 
studied doses. The number, severity and type of 
reported adverse events did not differ between the 
studied products and the reference drug, except 
for local events, which were reported the most 
seldom for fluticasone administered through the 
new generation cyclohaler at a dose of 250 μg 
BID. The absence of significant changes in corti-
sol level in urine and in serum after 12 weeks of 
treatment confirm the lack of any influence of the 
used therapy on the hypothalamic hypophyseal 
adrenal axis, and prove the high safety profile of 
the studied drug at the two doses.
Concluding, it may be stated that:
Fluticasone administered through a  new 
generation cyclohaler at doses of 125 and 250 μg 
BID is an efficient drug in the therapy of moderate 
bronchial asthma.
A dose of 250 μg BID of the new formula-
tion of fluticasone administered through a new 
generation cyclohaler is clinically equivalent to 
a twofold higher dose of fluticasone DPI.
The clinical activity of fluticasone 125 μg 
BID is not weaker than the activity of fluticasone 
DPI at a dose of 500 μg BID. There is no clinical-
ly significant difference in efficacy between the 
dose of 250 μg of fluticasone BID and the dose of 
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125 μg administered through the new generation 
cyclohaler, which arises from a flat dose-response 
curve in the range of medium and high doses for 
this drug.
Fluticasone administered through the new 
generation cyclohaler has a safety profile clini-
cally comparable to the reference drug.
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